Trial Outcomes & Findings for A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors (NCT NCT02549937)

Last Updated: 2024-07-10

Results Overview

A DLT was defined as any of the following toxicities determined by the Investigator to have a reasonable possibility of being related to surufatinib. Adverse events (AE) were graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Any Grade 4 non-hematological toxicity; any Grade 3 non-hematological toxicity except for nausea/vomiting, diarrhea, constipation, electrolyte imbalances, or transient hypertension downgraded within 3 days with appropriate supportive treatment; Grade 4 neutropenia lasting \>7 days; Grade 3 febrile neutropenia (absolute neutrophil count \<1.0 × 10\^9/liter (L) with a single temperature of \>38.3 degree Celsius (°C) or a sustained temperature of \>=38°C for more than 1 hour; Grade 4 thrombocytopenia or \>=Grade 3 thrombocytopenia associated with tendency to bleed; dose interruption or delay for \>14 days due to toxicity; any life-threatening complication or abnormality not covered in NCI CTCAE v. 4.03.

Recruitment status

COMPLETED

Study phase

PHASE1/PHASE2

Target enrollment

130 participants

Primary outcome timeframe

From the first dose of study drug (Day 1) up to Day 28 of Cycle 1

Results posted on

2024-07-10

Participant Flow

This Phase 1/1b, 2-part, open-label study was conducted in patients with advanced solid tumors at 12 investigational sites in the United States and Italy.

The study consisted of a Dose-Escalation phase in patients with advanced solid tumors of any type and a Dose-Expansion phase in patients with advanced biliary tract cancer (BTC) (Arm A), advanced pancreatic neuroendocrine tumor (pNETs) (Arm B), advanced extrapancreatic neuroendocrine tumor (epNETs) (Arm C), or soft tissue sarcoma (STS) (Arm D). A total of 35 patients in Dose-Escalation phase and 95 patients in Dose-Expansion phase were enrolled in this study.

Participant milestones

Participant milestones
Measure	Dose-Escalation Phase: Surufatinib 50 Milligrams (mg) Patients received surufatinib 50 mg orally once daily (QD) throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Overall Study STARTED	3	7	3	9	13	30	16	16	33
Overall Study COMPLETED	0	0	0	0	0	0	0	0	0
Overall Study NOT COMPLETED	3	7	3	9	13	30	16	16	33

Reasons for withdrawal

Reasons for withdrawal
Measure	Dose-Escalation Phase: Surufatinib 50 Milligrams (mg) Patients received surufatinib 50 mg orally once daily (QD) throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Overall Study Death	0	1	0	1	0	8	0	0	19
Overall Study No follow up required	3	6	3	8	12	21	9	11	0
Overall Study Other	0	0	0	0	1	0	3	2	3
Overall Study Lost to Follow-up	0	0	0	0	0	0	0	0	3
Overall Study Withdrawal by Subject	0	0	0	0	0	1	4	3	2
Overall Study Sponsor Decision	0	0	0	0	0	0	0	0	6

Baseline Characteristics

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Dose-Escalation Phase: Surufatinib 50 mg n=3 Participants Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg n=7 Participants Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg n=3 Participants Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg n=9 Participants Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg n=13 Participants Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC n=30 Participants Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET n=16 Participants Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET n=16 Participants Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS n=33 Participants Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Total n=130 Participants Total of all reporting groups
Age, Continuous	50.9 years STANDARD_DEVIATION 4.16 • n=5 Participants	58.1 years STANDARD_DEVIATION 8.27 • n=7 Participants	61.3 years STANDARD_DEVIATION 7.04 • n=5 Participants	62.6 years STANDARD_DEVIATION 11.91 • n=4 Participants	56.5 years STANDARD_DEVIATION 13.20 • n=21 Participants	65.6 years STANDARD_DEVIATION 10.67 • n=8 Participants	60.5 years STANDARD_DEVIATION 10.72 • n=8 Participants	61.4 years STANDARD_DEVIATION 9.62 • n=24 Participants	53.6 years STANDARD_DEVIATION 13.48 • n=42 Participants	59.4 years STANDARD_DEVIATION 12.07 • n=42 Participants
Sex: Female, Male Female	2 Participants n=5 Participants	6 Participants n=7 Participants	3 Participants n=5 Participants	5 Participants n=4 Participants	9 Participants n=21 Participants	16 Participants n=8 Participants	5 Participants n=8 Participants	5 Participants n=24 Participants	22 Participants n=42 Participants	73 Participants n=42 Participants
Sex: Female, Male Male	1 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	4 Participants n=4 Participants	4 Participants n=21 Participants	14 Participants n=8 Participants	11 Participants n=8 Participants	11 Participants n=24 Participants	11 Participants n=42 Participants	57 Participants n=42 Participants
Race/Ethnicity, Customized Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=8 Participants	2 Participants n=8 Participants	0 Participants n=24 Participants	1 Participants n=42 Participants	4 Participants n=42 Participants
Race/Ethnicity, Customized Black or African American	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	4 Participants n=24 Participants	1 Participants n=42 Participants	6 Participants n=42 Participants
Race/Ethnicity, Customized White	2 Participants n=5 Participants	7 Participants n=7 Participants	3 Participants n=5 Participants	9 Participants n=4 Participants	12 Participants n=21 Participants	29 Participants n=8 Participants	6 Participants n=8 Participants	9 Participants n=24 Participants	26 Participants n=42 Participants	103 Participants n=42 Participants
Race/Ethnicity, Customized Other	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	3 Participants n=24 Participants	2 Participants n=42 Participants	6 Participants n=42 Participants
Race/Ethnicity, Customized Not Reported	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	8 Participants n=8 Participants	0 Participants n=24 Participants	2 Participants n=42 Participants	12 Participants n=42 Participants
Race/Ethnicity, Customized Missing	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	1 Participants n=42 Participants	1 Participants n=42 Participants
Race/Ethnicity, Customized Hispanic or Latino	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	4 Participants n=8 Participants	1 Participants n=8 Participants	4 Participants n=24 Participants	7 Participants n=42 Participants	18 Participants n=42 Participants
Race/Ethnicity, Customized Not Hispanic or Latino	2 Participants n=5 Participants	6 Participants n=7 Participants	2 Participants n=5 Participants	9 Participants n=4 Participants	11 Participants n=21 Participants	26 Participants n=8 Participants	7 Participants n=8 Participants	12 Participants n=24 Participants	24 Participants n=42 Participants	99 Participants n=42 Participants
Race/Ethnicity, Customized Unknown	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants

PRIMARY outcome

Timeframe: From the first dose of study drug (Day 1) up to Day 28 of Cycle 1

Population: The DLT Evaluable set included all patients in Safety analysis set who were evaluable for DLT assessment. A patient was DLT evaluable if: had not received any preventive treatment during the DLT period and had completed the first 28-day treatment cycle with complete safety evaluations and had received at least 75% of the assigned surufatinib dose or had a confirmed DLT during the first 28-day treatment cycle.

Outcome measures

Outcome measures
Measure	Dose-Escalation Phase: Surufatinib 50 mg n=3 Participants Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg n=6 Participants Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg n=3 Participants Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg n=9 Participants Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg n=11 Participants Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Dose-Escalation Phase: Number of Patients With Dose-Limiting Toxicities (DLTs)	0 Participants	1 Participants	0 Participants	1 Participants	3 Participants	—	—	—	—

PRIMARY outcome

Timeframe: From the first dose of study drug (Day 1) up to approximately 90 months

Population: The Safety analysis set included all patients who received at least 1 dose of surufatinib.

An AE was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug or other protocol-imposed drug, regardless of attribution. An SAE was an AE that resulted in any of the following outcomes: was fatal; was life threatening; required or prolonged inpatient hospitalization; resulted in persistent or significant disability/incapacity; a congenital anomaly/birth defect in a neonate/infant born to a female patient or female partner of a male patient exposed to the study drug(s); was considered a significant medical event by the Investigator. TEAEs were defined as any AEs that started or worsened in severity on or after the first administration date of study drug and no later than 30 (+7) days after the last administration date of study drug or initiation of new anti-tumor therapy (whichever occurred first).

Outcome measures

Outcome measures
Measure	Dose-Escalation Phase: Surufatinib 50 mg n=3 Participants Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg n=7 Participants Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg n=3 Participants Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg n=9 Participants Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg n=13 Participants Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Dose-Escalation Phase: Number of Patients With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) Any TEAEs	3 Participants	7 Participants	3 Participants	9 Participants	13 Participants	—	—	—	—
Dose-Escalation Phase: Number of Patients With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) Any TESAEs	1 Participants	2 Participants	0 Participants	4 Participants	4 Participants	—	—	—	—

PRIMARY outcome

Timeframe: At 16 weeks

Population: The Safety analysis set included all patients who received at least 1 dose of surufatinib.

The tumor response was determined according to the international Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 guideline. PFS is defined as the time (in months) from the start date of study medication (Day 1) until the date of objective disease progression as defined by RECIST Version 1.1 or death (by any cause in the absence of progression), whichever occurred earlier. PFS rate probability at 16 week was estimated. Progression is defined by RECIST v1.0 as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline or appearance of 1 or more new lesions.

Outcome measures

Outcome measures
Measure	Dose-Escalation Phase: Surufatinib 50 mg n=30 Participants Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg n=33 Participants Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Dose-Expansion Phase: Arms A and D: Progression Free Survival (PFS) Rate at 16 Weeks	50.1 percentage of patients Interval 27.8 to 68.9	26.5 percentage of patients Interval 11.4 to 44.2	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: At 11 months

Population: The Safety analysis set included all patients who received at least 1 dose of surufatinib.

The tumor response was determined according to the RECIST v1.1 guideline. PFS is defined as the time (in months) from the start date of study medication (Day 1) until the date of objective disease progression as defined by RECIST Version 1.1 or death (by any cause in the absence of progression), whichever occurred earlier. PFS rate probability at 11 months was estimated. Progression is defined by RECIST v1.0 as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline or appearance of 1 or more new lesions.

Outcome measures

Outcome measures
Measure	Dose-Escalation Phase: Surufatinib 50 mg n=16 Participants Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg n=16 Participants Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Dose-Expansion Phase: Arms B and C: PFS Rate at 11 Months	64.6 percentage of patients Interval 34.7 to 83.5	60.9 percentage of patients Interval 24.3 to 84.0	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 1, 2, 4, 6, 8 hours post-dose on Days 1 and 15 of Cycle 1

Population: The PK analysis set included all patients whose plasma samples were collected for surufatinib concentration measurement and derivation of PK parameters. Combined data is presented for all patients evaluable for PK parameters who received surufatinib 300 mg in Dose-Escalation and Dose-Expansion phase. Only those patients with data collected at specified timepoints are reported.

Plasma samples were collected to determine Cmax of surufatinib. The pharmacokinetic (PK) parameters were determined by non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dose-Escalation Phase: Surufatinib 50 mg n=3 Participants Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg n=7 Participants Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg n=3 Participants Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg n=79 Participants Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg n=13 Participants Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Dose-Escalation and Dose-Expansion Phase: Maximum Observed Plasma Concentration (Cmax) of Surufatinib Cycle 1 Day 1	73.6 nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 39.2	149 nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 107.3	180 nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 39.3	364 nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 66.6	427 nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 82.9	—	—	—	—
Dose-Escalation and Dose-Expansion Phase: Maximum Observed Plasma Concentration (Cmax) of Surufatinib Cycle 1 Day 15	99.0 nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 16.9	167 nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 109.0	261 nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 43.6	456 nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 68.0	566 nanogram/milliliter (ng/mL) Geometric Coefficient of Variation 71.0	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 1, 2, 4, 6, and 8 hours post-dose on Days 1 and 15 of Cycle 1

Plasma samples were collected to determine Tmax of surufatinib. The PK parameters were determined by non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dose-Escalation Phase: Surufatinib 50 mg n=3 Participants Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg n=7 Participants Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg n=3 Participants Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg n=79 Participants Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg n=13 Participants Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Dose Escalation and Dose-Expansion Phase: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Surufatinib Cycle 1 Day 15	3.98 hour Interval 1.97 to 4.0	2.00 hour Interval 0.98 to 3.88	2.03 hour Interval 1.0 to 2.12	3.50 hour Interval 0.73 to 7.88	4.00 hour Interval 2.0 to 7.07	—	—	—	—
Dose Escalation and Dose-Expansion Phase: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Surufatinib Cycle 1 Day 1	2.00 hour Interval 1.02 to 2.17	1.03 hour Interval 1.0 to 4.0	2.05 hour Interval 1.02 to 3.58	2.20 hour Interval 0.75 to 23.7	3.83 hour Interval 1.18 to 8.13	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 1

Plasma samples were collected to determine AUC0-24h of surufatinib. The PK parameters were determined by non-compartmental analysis. Data from pre-dose to 8 hours post-dose were extrapolated to obtain the AUC0-24 data.

Outcome measures

Outcome measures
Measure	Dose-Escalation Phase: Surufatinib 50 mg n=3 Participants Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg n=7 Participants Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg n=3 Participants Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg n=68 Participants Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg n=12 Participants Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Dose-Escalation and Dose-Expansion Phase: Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24h) of Surufatinib	616 hour*ng/mL Geometric Coefficient of Variation 7.5	877 hour*ng/mL Geometric Coefficient of Variation 81.2	1360 hour*ng/mL Geometric Coefficient of Variation 10.5	3080 hour*ng/mL Geometric Coefficient of Variation 58.8	3540 hour*ng/mL Geometric Coefficient of Variation 76.8	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose and 1, 2, 4, 6, and 8 hours post-dose on Day 15 of Cycle 1

Plasma samples were collected to determine AUCtau of surufatinib. The PK parameters were determined by non-compartmental analysis.

Outcome measures

Outcome measures
Measure	Dose-Escalation Phase: Surufatinib 50 mg n=3 Participants Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg n=7 Participants Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg n=3 Participants Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg n=67 Participants Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg n=10 Participants Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Dose-Escalation and Dose-Expansion Phase: AUC Over the Dosing Interval (AUCtau) of Surufatinib	968 hour*ng/mL Geometric Coefficient of Variation 1.5	1320 hour*ng/mL Geometric Coefficient of Variation 95.2	2310 hour*ng/mL Geometric Coefficient of Variation 36.7	4770 hour*ng/mL Geometric Coefficient of Variation 64.4	6890 hour*ng/mL Geometric Coefficient of Variation 60.5	—	—	—	—

SECONDARY outcome

Timeframe: RECIST assessments performed at screening (within 28 days before start of study treatment), Day 1 of Cycle 2, and every 8 (+/-1 week) weeks afterwards until the occurrence of disease progression, up to a maximum of 90 months

Population: The Efficacy analysis set included all patients who received at least 1 dose of surufatinib and had at least 1 post-baseline tumor assessment.

The ORR was defined as the percentage of patients achieving a complete response (CR) or partial response (PR) as confirmed best overall response (BOR) as determined by the Investigator using RECIST v1.1. The BOR was defined as the best response recorded from the start of study treatment until documented RECIST version 1.1 progression, death, or withdrawal of consent. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Outcome measures

Outcome measures
Measure	Dose-Escalation Phase: Surufatinib 50 mg n=3 Participants Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg n=6 Participants Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg n=3 Participants Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg n=8 Participants Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg n=11 Participants Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC n=27 Participants Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET n=16 Participants Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET n=16 Participants Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS n=30 Participants Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Dose-Escalation and Dose-Expansion Phase: Objective Response Rate (ORR)	0.0 percentage of patients Interval 0.0 to 70.8	0.0 percentage of patients Interval 0.0 to 45.9	0.0 percentage of patients Interval 0.0 to 70.8	0.0 percentage of patients Interval 0.0 to 36.9	9.1 percentage of patients Interval 0.2 to 41.3	0.0 percentage of patients Interval 0.0 to 12.8	18.8 percentage of patients Interval 4.0 to 45.6	6.3 percentage of patients Interval 0.2 to 30.2	0.0 percentage of patients Interval 0.0 to 11.6

SECONDARY outcome

Population: The Efficacy analysis set included all patients who received at least 1 dose of surufatinib and had at least 1 post-baseline tumor assessment.

The DCR was defined as the percentage of patients who achieved a CR, PR or stable disease (SD) as confirmed BOR as determined by the Investigator using RECIST v1.1. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum on study.

Outcome measures

Outcome measures
Measure	Dose-Escalation Phase: Surufatinib 50 mg n=3 Participants Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg n=6 Participants Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg n=3 Participants Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg n=8 Participants Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg n=11 Participants Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC n=27 Participants Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET n=16 Participants Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET n=16 Participants Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS n=30 Participants Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Dose-Escalation and Dose-Expansion Phase: Disease Control Rate (DCR)	33.3 percentage of patients Interval 0.8 to 90.6	50.0 percentage of patients Interval 11.8 to 88.2	33.3 percentage of patients Interval 0.8 to 90.6	50.0 percentage of patients Interval 15.7 to 84.3	72.7 percentage of patients Interval 39.0 to 94.0	48.1 percentage of patients Interval 28.7 to 68.1	87.5 percentage of patients Interval 61.7 to 98.4	93.8 percentage of patients Interval 69.8 to 99.8	30.0 percentage of patients Interval 14.7 to 49.4

SECONDARY outcome

Population: The Efficacy analysis set included all patients who received at least 1 dose of surufatinib and had at least 1 post-baseline tumor assessment. Only those patients with PR or CR (responders) were included in the analysis.

The DoR was defined as the time from the first time that the objective response reached CR or PR, whichever came first (and later confirmed), until the occurrence of PD or death. The CR was defined as disappearance of all target lesions. The PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. The PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (nadir), including baseline. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters. The appearance of 1 or more new lesions was also considered progression.

Outcome measures

Outcome measures
Measure	Dose-Escalation Phase: Surufatinib 50 mg Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg n=1 Participants Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET n=3 Participants Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET n=1 Participants Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Dose-Escalation and Dose-Expansion Phase: Duration of Response (DoR)	—	—	—	—	13.142 months NA indicates that upper and lower limits of confidence interval (CI) were not estimable due to insufficient number of patients with events at study closure.	—	NA months Interval 14.752 to NA indicates that median and upper limit of CI were not estimable due to insufficient number of patients with events at study closure.	14.784 months NA indicates that upper and lower limits of CI were not estimable due to insufficient number of patients with events at study closure.	—

SECONDARY outcome

Population: The Safety analysis set included all patients who received at least 1 dose of surufatinib.

The PFS was defined as the time from the start date of study drug until the date of objective PD as assessed by the Investigator using RECIST version 1.1 or death (by any cause in the absence of progression).

Outcome measures

Outcome measures
Measure	Dose-Escalation Phase: Surufatinib 50 mg n=3 Participants Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg n=7 Participants Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg n=3 Participants Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg n=9 Participants Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg n=13 Participants Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Dose-Escalation Phase: Progression-Free Survival (PFS)	2.793 months Interval 1.873 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	2.530 months Interval 0.887 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	5.322 months Interval 0.92 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	2.694 months Interval 1.676 to 3.68	8.378 months Interval 1.741 to NA indicates that upper limit of CI was not estimable due to insufficient number of patients with events at study closure.	—	—	—	—

SECONDARY outcome

Population: The Efficacy analysis set included all patients who received at least 1 dose of study medication and had at least 1 post-baseline tumor assessment. Only those patients who achieved CR/PR (responders) were included in the analysis.

The TTR was defined as the time from the start of study drug until first documented response (and later confirmed) according to RECIST v.1.1 for responders only.

Outcome measures

Outcome measures
Measure	Dose-Escalation Phase: Surufatinib 50 mg Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg n=3 Participants Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg n=1 Participants Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Dose-Expansion Phase: Time to Response (TTR)	—	2.760 months Interval 2.69 to 4.63	2.497 months Interval 2.497 to 2.497	—	—	—	—	—	—

SECONDARY outcome

Percentage change in tumor size was determined for patients with measurable disease at baseline and was derived at each visit by the percentage change in the sum of the diameters of target lesions compared to baseline, mean of maximum percentage change is presented. Baseline was defined as the last evaluable tumor assessment result obtained prior to the administration of study drug (including unscheduled assessments).

Outcome measures

Outcome measures
Measure	Dose-Escalation Phase: Surufatinib 50 mg n=1 Participants Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg n=6 Participants Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg n=3 Participants Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg n=8 Participants Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg n=11 Participants Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC n=25 Participants Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET n=16 Participants Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET n=16 Participants Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS n=30 Participants Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Dose-Escalation and Dose-Expansion Phase: Maximum Percentage Change From Baseline in Tumor Size as Per RECIST v1.1	-17.895 percentage change Standard Deviation NA NA indicates that standard deviation cannot be derived for a single patient.	-14.076 percentage change Standard Deviation 42.9290	2.925 percentage change Standard Deviation 19.8263	7.982 percentage change Standard Deviation 21.9026	-10.249 percentage change Standard Deviation 38.9841	-2.129 percentage change Standard Deviation 19.5407	-15.210 percentage change Standard Deviation 28.1133	-11.047 percentage change Standard Deviation 12.8727	6.658 percentage change Standard Deviation 25.1689

Adverse Events

Dose-Escalation Phase: Surufatinib 50 mg

Serious events: 1 serious events

Other events: 3 other events

Deaths: 0 deaths

Dose-Escalation Phase: Surufatinib 100 mg

Serious events: 2 serious events

Other events: 7 other events

Deaths: 1 deaths

Dose-Escalation Phase: Surufatinib 200 mg

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Dose-Escalation Phase: Surufatinib 300 mg

Serious events: 4 serious events

Other events: 9 other events

Deaths: 1 deaths

Dose-Escalation Phase: Surufatinib 400 mg

Serious events: 4 serious events

Other events: 13 other events

Deaths: 0 deaths

Dose-Expansion Phase: Arm A: BTC

Serious events: 11 serious events

Other events: 26 other events

Deaths: 8 deaths

Dose-Expansion Phase: Arm B: pNET

Serious events: 8 serious events

Other events: 15 other events

Deaths: 0 deaths

Dose-Expansion Phase: Arm C: epNET

Serious events: 7 serious events

Other events: 16 other events

Deaths: 0 deaths

Dose-Expansion Phase: Arm D: STS

Serious events: 15 serious events

Other events: 31 other events

Deaths: 20 deaths

Serious adverse events

Serious adverse events
Measure	Dose-Escalation Phase: Surufatinib 50 mg n=3 participants at risk Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg n=7 participants at risk Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg n=3 participants at risk Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg n=9 participants at risk Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg n=13 participants at risk Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC n=30 participants at risk Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET n=16 participants at risk Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET n=16 participants at risk Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS n=33 participants at risk Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Infections and infestations Epiglottitis	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Infections and infestations Pneumonia	33.3% 1/3 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	11.1% 1/9 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Infections and infestations Bacteraemia	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	14.3% 1/7 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	14.3% 1/7 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	11.1% 1/9 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.1% 2/33 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Respiratory, thoracic and mediastinal disorders Dyspnoea	33.3% 1/3 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Gastrointestinal disorders Ascites	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	11.1% 1/9 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	7.7% 1/13 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
General disorders Disease progression	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	14.3% 1/7 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	11.1% 1/9 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.3% 1/30 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Vascular disorders Hypertension	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	7.7% 1/13 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Vascular disorders Hypertensive crisis	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	11.1% 1/9 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Cardiac disorders Pericardial effusion	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	11.1% 1/9 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Nervous system disorders Posterior reversible encephalopathy syndrome	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	7.7% 1/13 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Renal and urinary disorders Proteinuria	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	7.7% 1/13 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Infections and infestations Sepsis	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.3% 1/30 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Infections and infestations Appendicitis	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Infections and infestations COVID-19	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Infections and infestations Cellulitis	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Infections and infestations Pharyngitis streptococcal	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
General disorders Non-cardiac chest pain	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
General disorders Oedema peripheral	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant neoplasm progression	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.1% 2/33 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to central nervous system	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.3% 1/30 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm progression	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Gastrointestinal disorders Dysphagia	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Gastrointestinal disorders Nausea	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Gastrointestinal disorders Oral pain	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Gastrointestinal disorders Vomiting	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Hepatobiliary disorders Biliary obstruction	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	10.0% 3/30 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Hepatobiliary disorders Cholangitis	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.3% 1/30 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Metabolism and nutrition disorders Dehydration	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.3% 1/30 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.3% 1/30 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Nervous system disorders Haemorrhage intracranial	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Nervous system disorders Spinal cord compression	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Nervous system disorders Subarachnoid haemorrhage	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Cardiac disorders Atrial fibrillation	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Cardiac disorders Myocardial infarction	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.3% 1/30 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Injury, poisoning and procedural complications Spinal fracture	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Injury, poisoning and procedural complications Subdural haemorrhage	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.3% 1/30 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Investigations Blood bilirubin increased	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Investigations Ejection fraction decreased	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Renal and urinary disorders Haematuria	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Renal and urinary disorders Nephrolithiasis	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Renal and urinary disorders Urinary retention	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Reproductive system and breast disorders Benign prostatic hyperplasia	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Reproductive system and breast disorders Oedema genital	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Eye disorders Diplopia	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.

Other adverse events

Other adverse events
Measure	Dose-Escalation Phase: Surufatinib 50 mg n=3 participants at risk Patients received surufatinib 50 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment that the patient can no longer benefit from the study drug.	Dose-Escalation Phase: Surufatinib 100 mg n=7 participants at risk Patients received surufatinib 100 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 200 mg n=3 participants at risk Patients received surufatinib 200 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 300 mg n=9 participants at risk Patients received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Escalation Phase: Surufatinib 400 mg n=13 participants at risk Patients received surufatinib 400 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm A: BTC n=30 participants at risk Patients with advanced BTC received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm B: pNET n=16 participants at risk Patients with advanced pNET received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm C: epNET n=16 participants at risk Patients with advanced epNETs received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.	Dose-Expansion Phase: Arm D: STS n=33 participants at risk Patients with STS received surufatinib 300 mg orally QD throughout each 28-day treatment cycle until disease progression, death, intolerable toxicity, pregnancy, withdrawal of consent, or an Investigator's assessment of loss of benefit from the study drug.
Gastrointestinal disorders Nausea	33.3% 1/3 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	57.1% 4/7 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	33.3% 1/3 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	44.4% 4/9 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	53.8% 7/13 • Number of events 9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	26.7% 8/30 • Number of events 8 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	31.2% 5/16 • Number of events 6 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	31.2% 5/16 • Number of events 9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.2% 6/33 • Number of events 6 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Gastrointestinal disorders Diarrhoea	33.3% 1/3 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	42.9% 3/7 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	22.2% 2/9 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	76.9% 10/13 • Number of events 18 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	36.7% 11/30 • Number of events 18 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	43.8% 7/16 • Number of events 10 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	37.5% 6/16 • Number of events 11 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	27.3% 9/33 • Number of events 15 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Gastrointestinal disorders Vomiting	100.0% 3/3 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	14.3% 1/7 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	33.3% 1/3 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	33.3% 3/9 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	30.8% 4/13 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	23.3% 7/30 • Number of events 8 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	25.0% 4/16 • Number of events 6 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	31.2% 5/16 • Number of events 6 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	9.1% 3/33 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Gastrointestinal disorders Abdominal pain	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	28.6% 2/7 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	33.3% 1/3 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	22.2% 2/9 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	23.1% 3/13 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	13.3% 4/30 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	43.8% 7/16 • Number of events 11 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	37.5% 6/16 • Number of events 7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	9.1% 3/33 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Gastrointestinal disorders Constipation	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	14.3% 1/7 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	22.2% 2/9 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	15.4% 2/13 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	16.7% 5/30 • Number of events 6 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	25.0% 4/16 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	25.0% 4/16 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.1% 2/33 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Gastrointestinal disorders Abdominal distension	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	14.3% 1/7 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	33.3% 1/3 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	22.2% 2/9 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	10.0% 3/30 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	31.2% 5/16 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	28.6% 2/7 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	11.1% 1/9 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	7.7% 1/13 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.1% 2/33 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Gastrointestinal disorders Dry mouth	33.3% 1/3 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	15.4% 2/13 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.3% 1/30 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Gastrointestinal disorders Flatulence	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.7% 2/30 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.1% 2/33 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
General disorders Fatigue	33.3% 1/3 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	57.1% 4/7 • Number of events 8 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	22.2% 2/9 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	46.2% 6/13 • Number of events 9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	26.7% 8/30 • Number of events 13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	31.2% 5/16 • Number of events 11 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	62.5% 10/16 • Number of events 14 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	39.4% 13/33 • Number of events 16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
General disorders Oedema peripheral	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	14.3% 1/7 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	22.2% 2/9 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	23.1% 3/13 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	20.0% 6/30 • Number of events 7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	37.5% 6/16 • Number of events 6 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.2% 6/33 • Number of events 6 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
General disorders Pyrexia	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	30.8% 4/13 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	10.0% 3/30 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
General disorders Chills	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	15.4% 2/13 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.7% 2/30 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
General disorders Asthenia	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	7.7% 1/13 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.7% 2/30 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.1% 2/33 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Metabolism and nutrition disorders Dehydration	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	28.6% 2/7 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	33.3% 3/9 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	15.4% 2/13 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	10.0% 3/30 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/33 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Metabolism and nutrition disorders Decreased appetite	33.3% 1/3 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	11.1% 1/9 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	23.1% 3/13 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	16.7% 5/30 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	25.0% 4/16 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	31.2% 5/16 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	9.1% 3/33 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Metabolism and nutrition disorders Hypertriglyceridaemia	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	15.4% 2/13 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.3% 1/30 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	25.0% 4/16 • Number of events 6 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	9.1% 3/33 • Number of events 7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	14.3% 1/7 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.3% 1/30 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.1% 2/33 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Musculoskeletal and connective tissue disorders Arthralgia	33.3% 1/3 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	23.1% 3/13 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	16.7% 5/30 • Number of events 6 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	31.2% 5/16 • Number of events 6 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.1% 4/33 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	33.3% 1/3 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	23.1% 3/13 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.7% 2/30 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	33.3% 1/3 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	11.1% 1/9 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	7.7% 1/13 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.3% 1/30 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.1% 2/33 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	14.3% 1/7 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	33.3% 1/3 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	13.3% 4/30 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.2% 6/33 • Number of events 6 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Nervous system disorders Headache	66.7% 2/3 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	14.3% 1/7 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	33.3% 1/3 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	22.2% 2/9 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	23.1% 3/13 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	13.3% 4/30 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	37.5% 6/16 • Number of events 7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	25.0% 4/16 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	15.2% 5/33 • Number of events 8 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Nervous system disorders Dizziness	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	28.6% 2/7 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	11.1% 1/9 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	15.4% 2/13 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.7% 2/30 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.1% 2/33 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	22.2% 2/9 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	23.1% 3/13 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.3% 1/30 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.1% 2/33 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Respiratory, thoracic and mediastinal disorders Dyspnoea	33.3% 1/3 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	22.2% 2/9 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	15.2% 5/33 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	11.1% 1/9 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	7.7% 1/13 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	15.2% 5/33 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Vascular disorders Hypertension	33.3% 1/3 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	33.3% 3/9 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	30.8% 4/13 • Number of events 7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	43.3% 13/30 • Number of events 17 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	50.0% 8/16 • Number of events 10 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	43.8% 7/16 • Number of events 10 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	36.4% 12/33 • Number of events 15 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Renal and urinary disorders Proteinuria	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	38.5% 5/13 • Number of events 11 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	26.7% 8/30 • Number of events 21 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	50.0% 8/16 • Number of events 22 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	43.8% 7/16 • Number of events 15 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	21.2% 7/33 • Number of events 7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Renal and urinary disorders Haematuria	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	14.3% 1/7 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	10.0% 3/30 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	9.1% 3/33 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Investigations Alanine aminotransferase increased	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	23.1% 3/13 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.3% 1/30 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Investigations Aspartate aminotransferase increased	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	15.4% 2/13 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.3% 1/30 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 6 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Investigations Blood bilirubin increased	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	7.7% 1/13 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	16.7% 5/30 • Number of events 15 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.2% 6/33 • Number of events 8 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Investigations Platelet count decreased	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	7.7% 1/13 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	10.0% 3/30 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Investigations Weight decreased	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	7.7% 1/13 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/30 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	25.0% 4/16 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.0% 1/33 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Investigations Blood creatinine increased	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/13 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.7% 2/30 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	25.0% 4/16 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	9.1% 3/33 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Endocrine disorders Hypothyroidism	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	23.1% 3/13 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.7% 2/30 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.1% 2/33 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Infections and infestations Urinary tract infection	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	14.3% 1/7 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	15.4% 2/13 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	10.0% 3/30 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	6.2% 1/16 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.5% 2/16 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.1% 4/33 • Number of events 4 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Blood and lymphatic system disorders Anaemia	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	11.1% 1/9 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	7.7% 1/13 • Number of events 2 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	10.0% 3/30 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 6 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	18.8% 3/16 • Number of events 5 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	12.1% 4/33 • Number of events 7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.
Skin and subcutaneous tissue disorders Rash	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/7 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/9 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	7.7% 1/13 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	3.3% 1/30 • Number of events 1 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	31.2% 5/16 • Number of events 6 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	0.00% 0/16 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.	9.1% 3/33 • Number of events 3 • TEAEs and all-cause mortality were collected from the first dose of study drug (Day 1) up to approximately 90 months The Safety analysis set included all patients who received at least 1 dose of surufatinib.

Additional Information

Martin Benes

HUTCHMED Limited

Phone: +1.973.306

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place